Use of immunoinformatics and the simulation approach to identify Helicobacter pylori epitopes to design a multi-epitope subunit vaccine for B- and T-cells

• Published in: BMC biotechnology 2023-09, Vol.23 (1), p.42-42, Article 42
• Main Authors: Chaleshtori, Zahra Ahmadzadeh, Rastegari, Ali Asghar, Nayeri, Hashem, Doosti, Abbas
• Format: Article
• Language: English
• Subjects: Analysis; Antibiotics; Antigenic determinants; Antigens; Apolipoproteins; Bacteria; Cancer; Care and treatment; Complications and side effects; Computer Simulation; Cytotoxicity; Design; Design improvements; Drug development; Epitopes; Genes; Gram-negative bacteria; Health aspects; Helicobacter infections; Helicobacter pylori; IceA1; IceA2; Immune response; Immune system; Immunogenicity; Immunoinformatics; Immunotherapy; Infection; Infections; LeoA; Lipoproteins; Lymphocytes T; Major histocompatibility complex; Malignancy; Medical research; Medicine, Experimental; Membranes; Pathogens; Patient outcomes; Prediction models; Proteins; Simulation; Stability analysis; T cells; T-Lymphocytes; Ulcers; Vaccine; Vaccines; Vaccines, Subunit
• ISSN: 1472-6750; 1472-6750
• DOI: 10.1186/s12896-023-00814-5

Helicobacter pylori cause a variety of gastric malignancies, gastric ulcers, and cause erosive diseases. The extreme nature of the bacterium and the implantation of this bacterium protects it against designing a potent drug against it. Therefore, employing a precise and effective design for a more safe and stable antigenic vaccine against this pathogen can effectively control its associated infections. This study, aimed at improving the design of multiple subunit vaccines against H. pylori, adopts multiple immunoinformatics approaches in combination with other computational approaches. In this regard, 10 HTL, and 11 CTL epitopes were employed based on appropriate adopted MHC binding scores and c-terminal cut-off scores of 4 main selected proteins (APO, LeoA, IceA1, and IceA2). An adjuvant was added to the N end of the vaccine to achieve higher stability. For validation, immunogenicity and sensitization of physicochemical analyses were performed. The vaccine could be antigenic with significantly strong interactions with TOLK-2, 4, 5, and 9 receptors. The designed vaccine was subjected to Gromacs simulation and immune response prediction modelling that confirmed expression and immune-stimulating response efficiency. Besides, the designed vaccine showed better interactions with TLK-9. Based on our analyses, although the suggested vaccine could induce a clear response against H. pylori, precise laboratory validation is required to confirm its immunogenicity and safety status.